Results 111 to 120 of about 43,525 (155)

Pharmacologic Targeting of BET Proteins Attenuates Hyperuricemic Nephropathy in Rats. [PDF]

Front Pharmacol, 2021
Xiong C, Deng J, Wang X, Shao X, Zhou Q, Zou H, Zhuang S.   +6 more
europepmc   +1 more source

Inhibition of bromodomain and extra-terminal proteins targets constitutively active NFκB and STAT signaling in lymphoma and influences the expression of the antiapoptotic proteins BCL2A1 and c-MYC

Cell Communication and Signaling
The antiapoptotic protein BCL2A1 is highly, but very heterogeneously expressed in Diffuse Large B-cell Lymphoma (DLBCL). Particularly in the context of resistance to current therapies, BCL2A1 appears to play an important role in protecting cancer cells ...
Nadja M. Pieper, Julia Schnell, Daniela Bruecher, Stefan Knapp, Meike Vogler   +4 more
doaj   +1 more source

Inhibition of BET Proteins during Adolescence Affects Prefrontal Cortical Development: Relevance to Schizophrenia. [PDF]

Int J Mol Sci, 2021
Bilecki W, Wawrzczak-Bargieła A, Majcher-Maślanka I, Chmelova M, Maćkowiak M.   +4 more
europepmc   +1 more source

Novel forms of prostate cancer chemoresistance to successful androgen deprivation therapy demand new approaches: Rationale for targeting BET proteins. [PDF]

Prostate, 2022
Mori JO, Shafran JS, Stojanova M, Katz MH, Gignac GA, Wisco JJ, Heaphy CM, Denis GV.   +7 more
europepmc   +1 more source

Discovery of a Positron Emission Tomography Radiotracer Selectively Targeting the BD1 Bromodomains of BET Proteins. [PDF]

ACS Med Chem Lett, 2021
Bai P, Lu X, Lu X, Liu Y, Lan Y, Wang H, Fiedler S, Striar R, Wang C.   +8 more
europepmc   +1 more source

Small-Molecule Natural Product Physachenolide C Potentiates Immunotherapy Efficacy by Targeting BET Proteins. [PDF]

Cancer Res, 2021
Tewary P, Brooks AD, Xu YM, Wijeratne EMK, Babyak AL, Back TC, Chari R, Evans CN, Henrich CJ, Meyer TJ, Edmondson EF, de Aquino MTP, Kanagasabai T, Shanker A, Gunatilaka AAL, Sayers TJ.   +15 more
europepmc   +1 more source

Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma. [PDF]

Mol Cancer Ther, 2021
Shigeta S, Lui GYL, Shaw R, Moser R, Gurley KE, Durenberger G, Rosati R, Diaz RL, Ince TA, Swisher EM, Grandori C, Kemp CJ.   +11 more
europepmc   +1 more source

Modulation of Bromo- and Extra-Terminal Domain (BET) Proteins Exerts Neuroprotective Effects in Cell Culture Models of Parkinson's Disease. [PDF]

Biomedicines
Martella N, Pensabene D, Colardo M, Muzzi M, Bisesto E, Varone M, Caretti G, Di Porzio A, Barrella V, Mazzoli A, Di Bartolomeo S, Moreno S, Segatto M.   +12 more
europepmc   +1 more source

Development of cell-active BRD4-D1 selective inhibitors to decode the role of BET proteins in LPS-mediated liver inflammation. [PDF]

Eur J Med Chem
Scholtz CR, Doskey LC, Kandanur SGS, Vail NR, Roderick ER, Peterson EJ, Hoell ZJ, Shi K, Aihara H, Kostallari E, Shah VH, Malhi H, Pomerantz WCK.   +12 more
europepmc   +1 more source

A "Goldilocks Zone" for Recruiting BET Proteins with Bromodomain-1-Selective Ligands. [PDF]

ACS Chem Biol
Mohammed A, Churion K, Danda A, Philips SJ, Ansari AZ.   +4 more
europepmc   +1 more source